Genomic	B:C0017428
complexity	O
and	O
targeted	O
genes	I:C1332838
in	O
anaplastic	O
thyroid	I:C0238461
cancer	I:C0238461
cell	O
lines	I:C0007634
.	O

Genomic	O
complexity	O
and	O
targeted	B:C1332838
genes	I:C1332838
in	O
anaplastic	O
thyroid	I:C0238461
cancer	I:C0238461
cell	O
lines	I:C0007634
.	O

Genomic	O
complexity	O
and	O
targeted	O
genes	I:C1332838
in	O
anaplastic	B:C0238461
thyroid	I:C0238461
cancer	I:C0238461
cell	O
lines	I:C0007634
.	O

Genomic	O
complexity	O
and	O
targeted	O
genes	I:C1332838
in	O
anaplastic	O
thyroid	I:C0238461
cancer	I:C0238461
cell	B:C0007634
lines	I:C0007634
.	O

Anaplastic	B:C0238461
thyroid	I:C0238461
cancer	I:C0238461
(	O
Anaplastic	O
thyroid	I:C0238461
cancer	I:C0238461
)	O
is	O
a	O
highly	O
malignant	O
disease	I:C0442867
with	O
a	O
very	O
short	O
median	O
survival	O
time	O
.	O

Anaplastic	O
thyroid	I:C0238461
cancer	I:C0238461
(	O
Anaplastic	B:C0238461
thyroid	I:C0238461
cancer	I:C0238461
)	O
is	O
a	O
highly	O
malignant	O
disease	I:C0442867
with	O
a	O
very	O
short	O
median	O
survival	O
time	O
.	O

Anaplastic	O
thyroid	I:C0238461
cancer	I:C0238461
(	O
Anaplastic	O
thyroid	I:C0238461
cancer	I:C0238461
)	O
is	O
a	O
highly	O
malignant	B:C0442867
disease	I:C0442867
with	O
a	O
very	O
short	O
median	O
survival	O
time	O
.	O

Few	O
studies	O
have	O
addressed	O
the	O
underlying	O
somatic	B:C0544886
mutations	I:C0544886
,	O
and	O
the	O
genomic	O
landscape	O
of	O
Anaplastic	O
thyroid	I:C0238461
cancer	I:C0238461
thus	O
remains	O
largely	O
unknown	O
.	O

Few	O
studies	O
have	O
addressed	O
the	O
underlying	O
somatic	O
mutations	I:C0544886
,	O
and	O
the	O
genomic	B:C0017428
landscape	O
of	O
Anaplastic	O
thyroid	I:C0238461
cancer	I:C0238461
thus	O
remains	O
largely	O
unknown	O
.	O

Few	O
studies	O
have	O
addressed	O
the	O
underlying	O
somatic	O
mutations	I:C0544886
,	O
and	O
the	O
genomic	O
landscape	O
of	O
Anaplastic	B:C0238461
thyroid	I:C0238461
cancer	I:C0238461
thus	O
remains	O
largely	O
unknown	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
have	O
ascertained	O
copy	O
number	O
aberrations	B:C0008625
,	O
gene	O
fusions	I:C0178648
,	O
gene	O
expression	I:C0752248
patterns	I:C0752248
,	O
and	O
mutations	O
in	O
early	O
-	O
passage	O
cells	I:C0007634
from	O
ten	O
newly	O
established	O
Anaplastic	O
thyroid	I:C0238461
cancer	I:C0238461
cell	O
lines	I:C0007634
using	O
single	O
nucleotide	I:C3536614
polymorphism	I:C3536614
(	I:C3536614
SNP	I:C3536614
)	I:C3536614
array	I:C3536614
analysis	I:C3536614
,	O
RNA	O
sequencing	I:C0162327
and	O
whole	O
exome	I:C3640077
sequencing	I:C3640077
.	O

In	O
the	O
present	O
study	O
,	O
we	O
have	O
ascertained	O
copy	O
number	O
aberrations	O
,	O
gene	B:C0178648
fusions	I:C0178648
,	O
gene	O
expression	I:C0752248
patterns	I:C0752248
,	O
and	O
mutations	O
in	O
early	O
-	O
passage	O
cells	I:C0007634
from	O
ten	O
newly	O
established	O
Anaplastic	O
thyroid	I:C0238461
cancer	I:C0238461
cell	O
lines	I:C0007634
using	O
single	O
nucleotide	I:C3536614
polymorphism	I:C3536614
(	I:C3536614
SNP	I:C3536614
)	I:C3536614
array	I:C3536614
analysis	I:C3536614
,	O
RNA	O
sequencing	I:C0162327
and	O
whole	O
exome	I:C3640077
sequencing	I:C3640077
.	O

In	O
the	O
present	O
study	O
,	O
we	O
have	O
ascertained	O
copy	O
number	O
aberrations	O
,	O
gene	O
fusions	I:C0178648
,	O
gene	B:C0752248
expression	I:C0752248
patterns	I:C0752248
,	O
and	O
mutations	O
in	O
early	O
-	O
passage	O
cells	I:C0007634
from	O
ten	O
newly	O
established	O
Anaplastic	O
thyroid	I:C0238461
cancer	I:C0238461
cell	O
lines	I:C0007634
using	O
single	O
nucleotide	I:C3536614
polymorphism	I:C3536614
(	I:C3536614
SNP	I:C3536614
)	I:C3536614
array	I:C3536614
analysis	I:C3536614
,	O
RNA	O
sequencing	I:C0162327
and	O
whole	O
exome	I:C3640077
sequencing	I:C3640077
.	O

In	O
the	O
present	O
study	O
,	O
we	O
have	O
ascertained	O
copy	O
number	O
aberrations	O
,	O
gene	O
fusions	I:C0178648
,	O
gene	O
expression	I:C0752248
patterns	I:C0752248
,	O
and	O
mutations	B:C0026882
in	O
early	O
-	O
passage	O
cells	I:C0007634
from	O
ten	O
newly	O
established	O
Anaplastic	O
thyroid	I:C0238461
cancer	I:C0238461
cell	O
lines	I:C0007634
using	O
single	O
nucleotide	I:C3536614
polymorphism	I:C3536614
(	I:C3536614
SNP	I:C3536614
)	I:C3536614
array	I:C3536614
analysis	I:C3536614
,	O
RNA	O
sequencing	I:C0162327
and	O
whole	O
exome	I:C3640077
sequencing	I:C3640077
.	O

In	O
the	O
present	O
study	O
,	O
we	O
have	O
ascertained	O
copy	O
number	O
aberrations	O
,	O
gene	O
fusions	I:C0178648
,	O
gene	O
expression	I:C0752248
patterns	I:C0752248
,	O
and	O
mutations	O
in	O
early	O
-	O
passage	B:C0007634
cells	I:C0007634
from	O
ten	O
newly	O
established	O
Anaplastic	O
thyroid	I:C0238461
cancer	I:C0238461
cell	O
lines	I:C0007634
using	O
single	O
nucleotide	I:C3536614
polymorphism	I:C3536614
(	I:C3536614
SNP	I:C3536614
)	I:C3536614
array	I:C3536614
analysis	I:C3536614
,	O
RNA	O
sequencing	I:C0162327
and	O
whole	O
exome	I:C3640077
sequencing	I:C3640077
.	O

In	O
the	O
present	O
study	O
,	O
we	O
have	O
ascertained	O
copy	O
number	O
aberrations	O
,	O
gene	O
fusions	I:C0178648
,	O
gene	O
expression	I:C0752248
patterns	I:C0752248
,	O
and	O
mutations	O
in	O
early	O
-	O
passage	O
cells	I:C0007634
from	O
ten	O
newly	O
established	O
Anaplastic	B:C0238461
thyroid	I:C0238461
cancer	I:C0238461
cell	O
lines	I:C0007634
using	O
single	O
nucleotide	I:C3536614
polymorphism	I:C3536614
(	I:C3536614
SNP	I:C3536614
)	I:C3536614
array	I:C3536614
analysis	I:C3536614
,	O
RNA	O
sequencing	I:C0162327
and	O
whole	O
exome	I:C3640077
sequencing	I:C3640077
.	O

In	O
the	O
present	O
study	O
,	O
we	O
have	O
ascertained	O
copy	O
number	O
aberrations	O
,	O
gene	O
fusions	I:C0178648
,	O
gene	O
expression	I:C0752248
patterns	I:C0752248
,	O
and	O
mutations	O
in	O
early	O
-	O
passage	O
cells	I:C0007634
from	O
ten	O
newly	O
established	O
Anaplastic	O
thyroid	I:C0238461
cancer	I:C0238461
cell	B:C0007634
lines	I:C0007634
using	O
single	O
nucleotide	I:C3536614
polymorphism	I:C3536614
(	I:C3536614
SNP	I:C3536614
)	I:C3536614
array	I:C3536614
analysis	I:C3536614
,	O
RNA	O
sequencing	I:C0162327
and	O
whole	O
exome	I:C3640077
sequencing	I:C3640077
.	O

In	O
the	O
present	O
study	O
,	O
we	O
have	O
ascertained	O
copy	O
number	O
aberrations	O
,	O
gene	O
fusions	I:C0178648
,	O
gene	O
expression	I:C0752248
patterns	I:C0752248
,	O
and	O
mutations	O
in	O
early	O
-	O
passage	O
cells	I:C0007634
from	O
ten	O
newly	O
established	O
Anaplastic	O
thyroid	I:C0238461
cancer	I:C0238461
cell	O
lines	I:C0007634
using	O
single	B:C3536614
nucleotide	I:C3536614
polymorphism	I:C3536614
(	I:C3536614
SNP	I:C3536614
)	I:C3536614
array	I:C3536614
analysis	I:C3536614
,	O
RNA	O
sequencing	I:C0162327
and	O
whole	O
exome	I:C3640077
sequencing	I:C3640077
.	O

In	O
the	O
present	O
study	O
,	O
we	O
have	O
ascertained	O
copy	O
number	O
aberrations	O
,	O
gene	O
fusions	I:C0178648
,	O
gene	O
expression	I:C0752248
patterns	I:C0752248
,	O
and	O
mutations	O
in	O
early	O
-	O
passage	O
cells	I:C0007634
from	O
ten	O
newly	O
established	O
Anaplastic	O
thyroid	I:C0238461
cancer	I:C0238461
cell	O
lines	I:C0007634
using	O
single	O
nucleotide	I:C3536614
polymorphism	I:C3536614
(	I:C3536614
SNP	I:C3536614
)	I:C3536614
array	I:C3536614
analysis	I:C3536614
,	O
RNA	B:C0162327
sequencing	I:C0162327
and	O
whole	O
exome	I:C3640077
sequencing	I:C3640077
.	O

In	O
the	O
present	O
study	O
,	O
we	O
have	O
ascertained	O
copy	O
number	O
aberrations	O
,	O
gene	O
fusions	I:C0178648
,	O
gene	O
expression	I:C0752248
patterns	I:C0752248
,	O
and	O
mutations	O
in	O
early	O
-	O
passage	O
cells	I:C0007634
from	O
ten	O
newly	O
established	O
Anaplastic	O
thyroid	I:C0238461
cancer	I:C0238461
cell	O
lines	I:C0007634
using	O
single	O
nucleotide	I:C3536614
polymorphism	I:C3536614
(	I:C3536614
SNP	I:C3536614
)	I:C3536614
array	I:C3536614
analysis	I:C3536614
,	O
RNA	O
sequencing	I:C0162327
and	O
whole	B:C3640077
exome	I:C3640077
sequencing	I:C3640077
.	O

The	O
Anaplastic	B:C0238461
thyroid	I:C0238461
cancer	I:C0238461
cell	O
line	I:C0007634
genomes	O
were	O
highly	O
complex	O
and	O
displayed	O
signs	O
of	O
replicative	O
stress	O
and	O
genomic	O
instability	I:C0919532
,	O
including	O
massive	O
aneuploidy	O
and	O
frequent	O
breakpoints	O
in	O
the	O
centromeric	O
regions	I:C2612372
and	O
in	O
fragile	O
sites	I:C0677504
.	O

The	O
Anaplastic	O
thyroid	I:C0238461
cancer	I:C0238461
cell	B:C0007634
line	I:C0007634
genomes	O
were	O
highly	O
complex	O
and	O
displayed	O
signs	O
of	O
replicative	O
stress	O
and	O
genomic	O
instability	I:C0919532
,	O
including	O
massive	O
aneuploidy	O
and	O
frequent	O
breakpoints	O
in	O
the	O
centromeric	O
regions	I:C2612372
and	O
in	O
fragile	O
sites	I:C0677504
.	O

The	O
Anaplastic	O
thyroid	I:C0238461
cancer	I:C0238461
cell	O
line	I:C0007634
genomes	B:C0017428
were	O
highly	O
complex	O
and	O
displayed	O
signs	O
of	O
replicative	O
stress	O
and	O
genomic	O
instability	I:C0919532
,	O
including	O
massive	O
aneuploidy	O
and	O
frequent	O
breakpoints	O
in	O
the	O
centromeric	O
regions	I:C2612372
and	O
in	O
fragile	O
sites	I:C0677504
.	O

The	O
Anaplastic	O
thyroid	I:C0238461
cancer	I:C0238461
cell	O
line	I:C0007634
genomes	O
were	O
highly	O
complex	O
and	O
displayed	O
signs	O
of	O
replicative	B:C0598312
stress	O
and	O
genomic	O
instability	I:C0919532
,	O
including	O
massive	O
aneuploidy	O
and	O
frequent	O
breakpoints	O
in	O
the	O
centromeric	O
regions	I:C2612372
and	O
in	O
fragile	O
sites	I:C0677504
.	O

The	O
Anaplastic	O
thyroid	I:C0238461
cancer	I:C0238461
cell	O
line	I:C0007634
genomes	O
were	O
highly	O
complex	O
and	O
displayed	O
signs	O
of	O
replicative	O
stress	B:C0243095
and	O
genomic	O
instability	I:C0919532
,	O
including	O
massive	O
aneuploidy	O
and	O
frequent	O
breakpoints	O
in	O
the	O
centromeric	O
regions	I:C2612372
and	O
in	O
fragile	O
sites	I:C0677504
.	O

The	O
Anaplastic	O
thyroid	I:C0238461
cancer	I:C0238461
cell	O
line	I:C0007634
genomes	O
were	O
highly	O
complex	O
and	O
displayed	O
signs	O
of	O
replicative	O
stress	O
and	O
genomic	B:C0919532
instability	I:C0919532
,	O
including	O
massive	O
aneuploidy	O
and	O
frequent	O
breakpoints	O
in	O
the	O
centromeric	O
regions	I:C2612372
and	O
in	O
fragile	O
sites	I:C0677504
.	O

The	O
Anaplastic	O
thyroid	I:C0238461
cancer	I:C0238461
cell	O
line	I:C0007634
genomes	O
were	O
highly	O
complex	O
and	O
displayed	O
signs	O
of	O
replicative	O
stress	O
and	O
genomic	O
instability	I:C0919532
,	O
including	O
massive	O
aneuploidy	B:C0002938
and	O
frequent	O
breakpoints	O
in	O
the	O
centromeric	O
regions	I:C2612372
and	O
in	O
fragile	O
sites	I:C0677504
.	O

The	O
Anaplastic	O
thyroid	I:C0238461
cancer	I:C0238461
cell	O
line	I:C0007634
genomes	O
were	O
highly	O
complex	O
and	O
displayed	O
signs	O
of	O
replicative	O
stress	O
and	O
genomic	O
instability	I:C0919532
,	O
including	O
massive	O
aneuploidy	O
and	O
frequent	O
breakpoints	O
in	O
the	O
centromeric	B:C2612372
regions	I:C2612372
and	O
in	O
fragile	O
sites	I:C0677504
.	O

The	O
Anaplastic	O
thyroid	I:C0238461
cancer	I:C0238461
cell	O
line	I:C0007634
genomes	O
were	O
highly	O
complex	O
and	O
displayed	O
signs	O
of	O
replicative	O
stress	O
and	O
genomic	O
instability	I:C0919532
,	O
including	O
massive	O
aneuploidy	O
and	O
frequent	O
breakpoints	O
in	O
the	O
centromeric	O
regions	I:C2612372
and	O
in	O
fragile	B:C0677504
sites	I:C0677504
.	O

Loss	B:C0524869
of	I:C0524869
heterozygosity	I:C0524869
involving	O
whole	O
chromosomes	I:C0450238
was	O
common	O
,	O
but	O
there	O
were	O
no	O
signs	O
of	O
previous	O
near	O
-	I:C3828843
haploidisation	I:C3828843
events	I:C3828843
or	O
chromothripsis	O
.	O

Loss	O
of	I:C0524869
heterozygosity	I:C0524869
involving	O
whole	B:C0450238
chromosomes	I:C0450238
was	O
common	O
,	O
but	O
there	O
were	O
no	O
signs	O
of	O
previous	O
near	O
-	I:C3828843
haploidisation	I:C3828843
events	I:C3828843
or	O
chromothripsis	O
.	O

Loss	O
of	I:C0524869
heterozygosity	I:C0524869
involving	O
whole	O
chromosomes	I:C0450238
was	O
common	O
,	O
but	O
there	O
were	O
no	B:C1513916
signs	O
of	O
previous	O
near	O
-	I:C3828843
haploidisation	I:C3828843
events	I:C3828843
or	O
chromothripsis	O
.	O

Loss	O
of	I:C0524869
heterozygosity	I:C0524869
involving	O
whole	O
chromosomes	I:C0450238
was	O
common	O
,	O
but	O
there	O
were	O
no	O
signs	O
of	O
previous	O
near	B:C3828843
-	I:C3828843
haploidisation	I:C3828843
events	I:C3828843
or	O
chromothripsis	O
.	O

Loss	O
of	I:C0524869
heterozygosity	I:C0524869
involving	O
whole	O
chromosomes	I:C0450238
was	O
common	O
,	O
but	O
there	O
were	O
no	O
signs	O
of	O
previous	O
near	O
-	I:C3828843
haploidisation	I:C3828843
events	I:C3828843
or	O
chromothripsis	B:C4277538
.	O

A	O
total	O
of	O
21	O
fusion	B:C1533585
genes	I:C1533585
were	O
detected	O
,	O
including	O
six	O
predicted	O
in	O
-	I:C0178648
frame	I:C0178648
fusions	I:C0178648
;	O
none	O
were	O
recurrent	O
.	O

A	O
total	O
of	O
21	O
fusion	O
genes	I:C1533585
were	O
detected	O
,	O
including	O
six	O
predicted	O
in	B:C0178648
-	I:C0178648
frame	I:C0178648
fusions	I:C0178648
;	O
none	O
were	O
recurrent	O
.	O

Global	B:C1880945
gene	I:C1880945
expression	I:C1880945
analysis	I:C1880945
showed	O
661	O
genes	O
to	O
be	O
differentially	O
expressed	O
between	O
Anaplastic	O
thyroid	I:C0238461
cancer	I:C0238461
and	O
papillary	O
thyroid	I:C0238463
cancer	I:C0238463
cell	O
lines	I:C0007634
,	O
with	O
pathway	O
enrichment	I:C0936012
analyses	I:C0936012
showing	O
downregulation	O
of	O
TP53	O
signalling	O
as	O
well	O
as	O
cell	O
adhesion	I:C0007578
molecules	I:C0007578
in	O
Anaplastic	O
thyroid	I:C0238461
cancer	I:C0238461
.	O

Global	O
gene	I:C1880945
expression	I:C1880945
analysis	I:C1880945
showed	O
661	O
genes	B:C0017337
to	O
be	O
differentially	O
expressed	O
between	O
Anaplastic	O
thyroid	I:C0238461
cancer	I:C0238461
and	O
papillary	O
thyroid	I:C0238463
cancer	I:C0238463
cell	O
lines	I:C0007634
,	O
with	O
pathway	O
enrichment	I:C0936012
analyses	I:C0936012
showing	O
downregulation	O
of	O
TP53	O
signalling	O
as	O
well	O
as	O
cell	O
adhesion	I:C0007578
molecules	I:C0007578
in	O
Anaplastic	O
thyroid	I:C0238461
cancer	I:C0238461
.	O

Global	O
gene	I:C1880945
expression	I:C1880945
analysis	I:C1880945
showed	O
661	O
genes	O
to	O
be	O
differentially	O
expressed	B:C0017262
between	O
Anaplastic	O
thyroid	I:C0238461
cancer	I:C0238461
and	O
papillary	O
thyroid	I:C0238463
cancer	I:C0238463
cell	O
lines	I:C0007634
,	O
with	O
pathway	O
enrichment	I:C0936012
analyses	I:C0936012
showing	O
downregulation	O
of	O
TP53	O
signalling	O
as	O
well	O
as	O
cell	O
adhesion	I:C0007578
molecules	I:C0007578
in	O
Anaplastic	O
thyroid	I:C0238461
cancer	I:C0238461
.	O

Global	O
gene	I:C1880945
expression	I:C1880945
analysis	I:C1880945
showed	O
661	O
genes	O
to	O
be	O
differentially	O
expressed	O
between	O
Anaplastic	B:C0238461
thyroid	I:C0238461
cancer	I:C0238461
and	O
papillary	O
thyroid	I:C0238463
cancer	I:C0238463
cell	O
lines	I:C0007634
,	O
with	O
pathway	O
enrichment	I:C0936012
analyses	I:C0936012
showing	O
downregulation	O
of	O
TP53	O
signalling	O
as	O
well	O
as	O
cell	O
adhesion	I:C0007578
molecules	I:C0007578
in	O
Anaplastic	O
thyroid	I:C0238461
cancer	I:C0238461
.	O

Global	O
gene	I:C1880945
expression	I:C1880945
analysis	I:C1880945
showed	O
661	O
genes	O
to	O
be	O
differentially	O
expressed	O
between	O
Anaplastic	O
thyroid	I:C0238461
cancer	I:C0238461
and	O
papillary	B:C0238463
thyroid	I:C0238463
cancer	I:C0238463
cell	O
lines	I:C0007634
,	O
with	O
pathway	O
enrichment	I:C0936012
analyses	I:C0936012
showing	O
downregulation	O
of	O
TP53	O
signalling	O
as	O
well	O
as	O
cell	O
adhesion	I:C0007578
molecules	I:C0007578
in	O
Anaplastic	O
thyroid	I:C0238461
cancer	I:C0238461
.	O

Global	O
gene	I:C1880945
expression	I:C1880945
analysis	I:C1880945
showed	O
661	O
genes	O
to	O
be	O
differentially	O
expressed	O
between	O
Anaplastic	O
thyroid	I:C0238461
cancer	I:C0238461
and	O
papillary	O
thyroid	I:C0238463
cancer	I:C0238463
cell	B:C0007634
lines	I:C0007634
,	O
with	O
pathway	O
enrichment	I:C0936012
analyses	I:C0936012
showing	O
downregulation	O
of	O
TP53	O
signalling	O
as	O
well	O
as	O
cell	O
adhesion	I:C0007578
molecules	I:C0007578
in	O
Anaplastic	O
thyroid	I:C0238461
cancer	I:C0238461
.	O

Global	O
gene	I:C1880945
expression	I:C1880945
analysis	I:C1880945
showed	O
661	O
genes	O
to	O
be	O
differentially	O
expressed	O
between	O
Anaplastic	O
thyroid	I:C0238461
cancer	I:C0238461
and	O
papillary	O
thyroid	I:C0238463
cancer	I:C0238463
cell	O
lines	I:C0007634
,	O
with	O
pathway	B:C0936012
enrichment	I:C0936012
analyses	I:C0936012
showing	O
downregulation	O
of	O
TP53	O
signalling	O
as	O
well	O
as	O
cell	O
adhesion	I:C0007578
molecules	I:C0007578
in	O
Anaplastic	O
thyroid	I:C0238461
cancer	I:C0238461
.	O

Global	O
gene	I:C1880945
expression	I:C1880945
analysis	I:C1880945
showed	O
661	O
genes	O
to	O
be	O
differentially	O
expressed	O
between	O
Anaplastic	O
thyroid	I:C0238461
cancer	I:C0238461
and	O
papillary	O
thyroid	I:C0238463
cancer	I:C0238463
cell	O
lines	I:C0007634
,	O
with	O
pathway	O
enrichment	I:C0936012
analyses	I:C0936012
showing	O
downregulation	B:C0013081
of	O
TP53	O
signalling	O
as	O
well	O
as	O
cell	O
adhesion	I:C0007578
molecules	I:C0007578
in	O
Anaplastic	O
thyroid	I:C0238461
cancer	I:C0238461
.	O

Global	O
gene	I:C1880945
expression	I:C1880945
analysis	I:C1880945
showed	O
661	O
genes	O
to	O
be	O
differentially	O
expressed	O
between	O
Anaplastic	O
thyroid	I:C0238461
cancer	I:C0238461
and	O
papillary	O
thyroid	I:C0238463
cancer	I:C0238463
cell	O
lines	I:C0007634
,	O
with	O
pathway	O
enrichment	I:C0936012
analyses	I:C0936012
showing	O
downregulation	O
of	O
TP53	B:C0079419
signalling	O
as	O
well	O
as	O
cell	O
adhesion	I:C0007578
molecules	I:C0007578
in	O
Anaplastic	O
thyroid	I:C0238461
cancer	I:C0238461
.	O

Global	O
gene	I:C1880945
expression	I:C1880945
analysis	I:C1880945
showed	O
661	O
genes	O
to	O
be	O
differentially	O
expressed	O
between	O
Anaplastic	O
thyroid	I:C0238461
cancer	I:C0238461
and	O
papillary	O
thyroid	I:C0238463
cancer	I:C0238463
cell	O
lines	I:C0007634
,	O
with	O
pathway	O
enrichment	I:C0936012
analyses	I:C0936012
showing	O
downregulation	O
of	O
TP53	O
signalling	B:C3537152
as	O
well	O
as	O
cell	O
adhesion	I:C0007578
molecules	I:C0007578
in	O
Anaplastic	O
thyroid	I:C0238461
cancer	I:C0238461
.	O

Global	O
gene	I:C1880945
expression	I:C1880945
analysis	I:C1880945
showed	O
661	O
genes	O
to	O
be	O
differentially	O
expressed	O
between	O
Anaplastic	O
thyroid	I:C0238461
cancer	I:C0238461
and	O
papillary	O
thyroid	I:C0238463
cancer	I:C0238463
cell	O
lines	I:C0007634
,	O
with	O
pathway	O
enrichment	I:C0936012
analyses	I:C0936012
showing	O
downregulation	O
of	O
TP53	O
signalling	O
as	O
well	O
as	O
cell	B:C0007578
adhesion	I:C0007578
molecules	I:C0007578
in	O
Anaplastic	O
thyroid	I:C0238461
cancer	I:C0238461
.	O

Global	O
gene	I:C1880945
expression	I:C1880945
analysis	I:C1880945
showed	O
661	O
genes	O
to	O
be	O
differentially	O
expressed	O
between	O
Anaplastic	O
thyroid	I:C0238461
cancer	I:C0238461
and	O
papillary	O
thyroid	I:C0238463
cancer	I:C0238463
cell	O
lines	I:C0007634
,	O
with	O
pathway	O
enrichment	I:C0936012
analyses	I:C0936012
showing	O
downregulation	O
of	O
TP53	O
signalling	O
as	O
well	O
as	O
cell	O
adhesion	I:C0007578
molecules	I:C0007578
in	O
Anaplastic	B:C0238461
thyroid	I:C0238461
cancer	I:C0238461
.	O

Besides	O
previously	O
known	O
driver	O
events	O
,	O
such	O
as	O
mutations	B:C0026882
in	O
BRAF	O
,	O
NRAS	O
,	O
TP53	O
and	O
the	O
TERT	O
promoter	O
,	O
we	O
identified	O
PTPRD	O
and	O
NEGR1	O
as	O
putative	O
novel	O
target	O
genes	I:C1332838
in	O
Anaplastic	O
thyroid	I:C0238461
cancer	I:C0238461
,	O
based	O
on	O
deletions	O
in	O
six	O
and	O
four	O
cell	O
lines	I:C0007634
,	O
respectively	O
;	O
the	O
latter	O
gene	O
also	O
carried	O
a	O
somatic	O
mutation	I:C0544886
in	O
one	O
cell	O
line	I:C0007634
.	O

Besides	O
previously	O
known	O
driver	O
events	O
,	O
such	O
as	O
mutations	O
in	O
BRAF	B:C0812241
,	O
NRAS	O
,	O
TP53	O
and	O
the	O
TERT	O
promoter	O
,	O
we	O
identified	O
PTPRD	O
and	O
NEGR1	O
as	O
putative	O
novel	O
target	O
genes	I:C1332838
in	O
Anaplastic	O
thyroid	I:C0238461
cancer	I:C0238461
,	O
based	O
on	O
deletions	O
in	O
six	O
and	O
four	O
cell	O
lines	I:C0007634
,	O
respectively	O
;	O
the	O
latter	O
gene	O
also	O
carried	O
a	O
somatic	O
mutation	I:C0544886
in	O
one	O
cell	O
line	I:C0007634
.	O

Besides	O
previously	O
known	O
driver	O
events	O
,	O
such	O
as	O
mutations	O
in	O
BRAF	O
,	O
NRAS	B:C0809246
,	O
TP53	O
and	O
the	O
TERT	O
promoter	O
,	O
we	O
identified	O
PTPRD	O
and	O
NEGR1	O
as	O
putative	O
novel	O
target	O
genes	I:C1332838
in	O
Anaplastic	O
thyroid	I:C0238461
cancer	I:C0238461
,	O
based	O
on	O
deletions	O
in	O
six	O
and	O
four	O
cell	O
lines	I:C0007634
,	O
respectively	O
;	O
the	O
latter	O
gene	O
also	O
carried	O
a	O
somatic	O
mutation	I:C0544886
in	O
one	O
cell	O
line	I:C0007634
.	O

Besides	O
previously	O
known	O
driver	O
events	O
,	O
such	O
as	O
mutations	O
in	O
BRAF	O
,	O
NRAS	O
,	O
TP53	B:C0079419
and	O
the	O
TERT	O
promoter	O
,	O
we	O
identified	O
PTPRD	O
and	O
NEGR1	O
as	O
putative	O
novel	O
target	O
genes	I:C1332838
in	O
Anaplastic	O
thyroid	I:C0238461
cancer	I:C0238461
,	O
based	O
on	O
deletions	O
in	O
six	O
and	O
four	O
cell	O
lines	I:C0007634
,	O
respectively	O
;	O
the	O
latter	O
gene	O
also	O
carried	O
a	O
somatic	O
mutation	I:C0544886
in	O
one	O
cell	O
line	I:C0007634
.	O

Besides	O
previously	O
known	O
driver	O
events	O
,	O
such	O
as	O
mutations	O
in	O
BRAF	O
,	O
NRAS	O
,	O
TP53	O
and	O
the	O
TERT	B:C1367342
promoter	O
,	O
we	O
identified	O
PTPRD	O
and	O
NEGR1	O
as	O
putative	O
novel	O
target	O
genes	I:C1332838
in	O
Anaplastic	O
thyroid	I:C0238461
cancer	I:C0238461
,	O
based	O
on	O
deletions	O
in	O
six	O
and	O
four	O
cell	O
lines	I:C0007634
,	O
respectively	O
;	O
the	O
latter	O
gene	O
also	O
carried	O
a	O
somatic	O
mutation	I:C0544886
in	O
one	O
cell	O
line	I:C0007634
.	O

Besides	O
previously	O
known	O
driver	O
events	O
,	O
such	O
as	O
mutations	O
in	O
BRAF	O
,	O
NRAS	O
,	O
TP53	O
and	O
the	O
TERT	O
promoter	B:C0086860
,	O
we	O
identified	O
PTPRD	O
and	O
NEGR1	O
as	O
putative	O
novel	O
target	O
genes	I:C1332838
in	O
Anaplastic	O
thyroid	I:C0238461
cancer	I:C0238461
,	O
based	O
on	O
deletions	O
in	O
six	O
and	O
four	O
cell	O
lines	I:C0007634
,	O
respectively	O
;	O
the	O
latter	O
gene	O
also	O
carried	O
a	O
somatic	O
mutation	I:C0544886
in	O
one	O
cell	O
line	I:C0007634
.	O

Besides	O
previously	O
known	O
driver	O
events	O
,	O
such	O
as	O
mutations	O
in	O
BRAF	O
,	O
NRAS	O
,	O
TP53	O
and	O
the	O
TERT	O
promoter	O
,	O
we	O
identified	O
PTPRD	B:C1419114
and	O
NEGR1	O
as	O
putative	O
novel	O
target	O
genes	I:C1332838
in	O
Anaplastic	O
thyroid	I:C0238461
cancer	I:C0238461
,	O
based	O
on	O
deletions	O
in	O
six	O
and	O
four	O
cell	O
lines	I:C0007634
,	O
respectively	O
;	O
the	O
latter	O
gene	O
also	O
carried	O
a	O
somatic	O
mutation	I:C0544886
in	O
one	O
cell	O
line	I:C0007634
.	O

Besides	O
previously	O
known	O
driver	O
events	O
,	O
such	O
as	O
mutations	O
in	O
BRAF	O
,	O
NRAS	O
,	O
TP53	O
and	O
the	O
TERT	O
promoter	O
,	O
we	O
identified	O
PTPRD	O
and	O
NEGR1	B:C1424887
as	O
putative	O
novel	O
target	O
genes	I:C1332838
in	O
Anaplastic	O
thyroid	I:C0238461
cancer	I:C0238461
,	O
based	O
on	O
deletions	O
in	O
six	O
and	O
four	O
cell	O
lines	I:C0007634
,	O
respectively	O
;	O
the	O
latter	O
gene	O
also	O
carried	O
a	O
somatic	O
mutation	I:C0544886
in	O
one	O
cell	O
line	I:C0007634
.	O

Besides	O
previously	O
known	O
driver	O
events	O
,	O
such	O
as	O
mutations	O
in	O
BRAF	O
,	O
NRAS	O
,	O
TP53	O
and	O
the	O
TERT	O
promoter	O
,	O
we	O
identified	O
PTPRD	O
and	O
NEGR1	O
as	O
putative	O
novel	O
target	B:C1332838
genes	I:C1332838
in	O
Anaplastic	O
thyroid	I:C0238461
cancer	I:C0238461
,	O
based	O
on	O
deletions	O
in	O
six	O
and	O
four	O
cell	O
lines	I:C0007634
,	O
respectively	O
;	O
the	O
latter	O
gene	O
also	O
carried	O
a	O
somatic	O
mutation	I:C0544886
in	O
one	O
cell	O
line	I:C0007634
.	O

Besides	O
previously	O
known	O
driver	O
events	O
,	O
such	O
as	O
mutations	O
in	O
BRAF	O
,	O
NRAS	O
,	O
TP53	O
and	O
the	O
TERT	O
promoter	O
,	O
we	O
identified	O
PTPRD	O
and	O
NEGR1	O
as	O
putative	O
novel	O
target	O
genes	I:C1332838
in	O
Anaplastic	B:C0238461
thyroid	I:C0238461
cancer	I:C0238461
,	O
based	O
on	O
deletions	O
in	O
six	O
and	O
four	O
cell	O
lines	I:C0007634
,	O
respectively	O
;	O
the	O
latter	O
gene	O
also	O
carried	O
a	O
somatic	O
mutation	I:C0544886
in	O
one	O
cell	O
line	I:C0007634
.	O

Besides	O
previously	O
known	O
driver	O
events	O
,	O
such	O
as	O
mutations	O
in	O
BRAF	O
,	O
NRAS	O
,	O
TP53	O
and	O
the	O
TERT	O
promoter	O
,	O
we	O
identified	O
PTPRD	O
and	O
NEGR1	O
as	O
putative	O
novel	O
target	O
genes	I:C1332838
in	O
Anaplastic	O
thyroid	I:C0238461
cancer	I:C0238461
,	O
based	O
on	O
deletions	B:C0008628
in	O
six	O
and	O
four	O
cell	O
lines	I:C0007634
,	O
respectively	O
;	O
the	O
latter	O
gene	O
also	O
carried	O
a	O
somatic	O
mutation	I:C0544886
in	O
one	O
cell	O
line	I:C0007634
.	O

Besides	O
previously	O
known	O
driver	O
events	O
,	O
such	O
as	O
mutations	O
in	O
BRAF	O
,	O
NRAS	O
,	O
TP53	O
and	O
the	O
TERT	O
promoter	O
,	O
we	O
identified	O
PTPRD	O
and	O
NEGR1	O
as	O
putative	O
novel	O
target	O
genes	I:C1332838
in	O
Anaplastic	O
thyroid	I:C0238461
cancer	I:C0238461
,	O
based	O
on	O
deletions	O
in	O
six	O
and	O
four	O
cell	B:C0007634
lines	I:C0007634
,	O
respectively	O
;	O
the	O
latter	O
gene	O
also	O
carried	O
a	O
somatic	O
mutation	I:C0544886
in	O
one	O
cell	O
line	I:C0007634
.	O

Besides	O
previously	O
known	O
driver	O
events	O
,	O
such	O
as	O
mutations	O
in	O
BRAF	O
,	O
NRAS	O
,	O
TP53	O
and	O
the	O
TERT	O
promoter	O
,	O
we	O
identified	O
PTPRD	O
and	O
NEGR1	O
as	O
putative	O
novel	O
target	O
genes	I:C1332838
in	O
Anaplastic	O
thyroid	I:C0238461
cancer	I:C0238461
,	O
based	O
on	O
deletions	O
in	O
six	O
and	O
four	O
cell	O
lines	I:C0007634
,	O
respectively	O
;	O
the	O
latter	O
gene	B:C0017337
also	O
carried	O
a	O
somatic	O
mutation	I:C0544886
in	O
one	O
cell	O
line	I:C0007634
.	O

Besides	O
previously	O
known	O
driver	O
events	O
,	O
such	O
as	O
mutations	O
in	O
BRAF	O
,	O
NRAS	O
,	O
TP53	O
and	O
the	O
TERT	O
promoter	O
,	O
we	O
identified	O
PTPRD	O
and	O
NEGR1	O
as	O
putative	O
novel	O
target	O
genes	I:C1332838
in	O
Anaplastic	O
thyroid	I:C0238461
cancer	I:C0238461
,	O
based	O
on	O
deletions	O
in	O
six	O
and	O
four	O
cell	O
lines	I:C0007634
,	O
respectively	O
;	O
the	O
latter	O
gene	O
also	O
carried	O
a	O
somatic	B:C0544886
mutation	I:C0544886
in	O
one	O
cell	O
line	I:C0007634
.	O

Besides	O
previously	O
known	O
driver	O
events	O
,	O
such	O
as	O
mutations	O
in	O
BRAF	O
,	O
NRAS	O
,	O
TP53	O
and	O
the	O
TERT	O
promoter	O
,	O
we	O
identified	O
PTPRD	O
and	O
NEGR1	O
as	O
putative	O
novel	O
target	O
genes	I:C1332838
in	O
Anaplastic	O
thyroid	I:C0238461
cancer	I:C0238461
,	O
based	O
on	O
deletions	O
in	O
six	O
and	O
four	O
cell	O
lines	I:C0007634
,	O
respectively	O
;	O
the	O
latter	O
gene	O
also	O
carried	O
a	O
somatic	O
mutation	I:C0544886
in	O
one	O
cell	B:C0007634
line	I:C0007634
.	O

Taken	O
together	O
,	O
our	O
data	O
provide	O
novel	O
insights	O
into	O
the	O
tumourigenesis	B:C0007621
of	O
Anaplastic	O
thyroid	I:C0238461
cancer	I:C0238461
and	O
may	O
be	O
used	O
to	O
identify	O
new	O
therapeutic	O
targets	O
.	O

Taken	O
together	O
,	O
our	O
data	O
provide	O
novel	O
insights	O
into	O
the	O
tumourigenesis	O
of	O
Anaplastic	B:C0238461
thyroid	I:C0238461
cancer	I:C0238461
and	O
may	O
be	O
used	O
to	O
identify	O
new	O
therapeutic	O
targets	O
.	O

